The JID opens its doors to high-quality randomized controlled clinical trials

Journal of Investigative Dermatology

Volumn 126, Issue 8, 2006, Pages 1683-1684

  Williams, Hywel ^a   Goldsmith, Lowell ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; AMMONIUM SUCCINIMIDO AURATE; GLOBOTRIAOSYLCERAMIDE; GOLD DERIVATIVE; PLACEBO; RECOMBINANT ALPHA GALACTOSIDASE A; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DERMATOLOGY; DOCTOR PATIENT RELATION; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HUMAN; LUPUS ERYTHEMATOSUS; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SKIN CAPILLARY; STANDARDIZATION;

EID: 33746142418     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700467     Document Type: Editorial

References (16)

1. Adetugbo K, Williams H (2000) How well are randomized controlled trials reported in the dermatology literature? Arch Dermatol 136:381-5
2. Blank H (1961) Clinical trials, a scientific discipline. J Invest Dermatol 37:235-40
3. Chalmers I (2004) In the dark: drug companies should be forced to publish all the results of clinical trials. New Sci 181:19
4. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R et al. (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet 364:911-2
5. Egger M, Juni P, Bartlett C, CONSORT Group (Consolidated Standards of Reporting of Trials) (2001) Value of flow diagrams in reports of randomized controlled trials. JAMA 285:1996-9
6. Hewitt C, Hahn S, Torgerson DJ, Watson J, Bland JM (2005) Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ 330:1057-8
7. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF et al. (2003) Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349:658-65
8. Hoare C, Li Wan Po A, Williams H (2000) Systematic review of treatments for atopic eczema. Health Technol Assess 4:1-191
9. Moher D, Schulz KF, Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191-4
10. Obermayer ME, Becker SW (1938) Ammonium succinimido-aurate: a gold compound of low toxicity. J Invest Dermatol 1:85-107
11. Ozolins M, Eady EA, Avery AJ, Cunliffe WJ, Li Wan Po A, O'Neill C et al. (2004) Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 364:2188-95
12. Pillsbury DM, Zimmerman MC, Baldridge GD (1950) Experimental controls in clinical dermatologic investigation. J Invest Dermatol 14:359-71
13. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J et al. (2006) Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 332:933-8
14. Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O'Callaghan M et al. (2004) Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 122:900-8
15. Williams HC, Stern RS (2005) Prospective trials registration. J Invest Dermatol 124:vii-x
16. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L et al. (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:1586-9